CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)

The purpose of this PMS registry, named e-CYPHER Stent Registry, is to collect post marketing surveillance data on the CYPHERTM Sirolimus-eluting Coronary Stent following marketing approval, when used in normal clinical practice within the labeled indications.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cypher stent

Exclusion criteria

Treatment and study plan

CYPHERTM Sirolimus-Eluting Coronary Stent

Device

Primary outcomes

MACE at 30 days, 6 months and 1 year.

Secondary outcomes

There is no pre-specified secondary outcome.

Sponsors and collaborators

Lead sponsor

Cordis US Corp.

Industry

Registry information

Important dates

Study start: 2003
Study completion: 2004
First posted: Oct 28, 2005
Registry last updated: Apr 4, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed